Seaport Therapeutics, Inc.

S-1 filed

Seaport Therapeutics, Inc. is conducting an initial public offering (IPO) of its common stock, transitioning from a confidential DRS/A filing to a public S-1 registration. The company focuses on developing novel therapeutics for neuropsychiatric disorders using its proprietary Glyph TM platform, which enhances drug bioavailability and reduces side effects. Its lead candidate, GlyphAllo (SPT-300), is in Phase 2b trials for major depressive disorder (MDD), with topline data expected in 2027. The filing highlights its status as an emerging growth company and outlines risks related to clinical trial outcomes, reliance on a single product candidate, and financial constraints.

DRS/A amended

Seaport Therapeutics, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its clinical-stage therapeutics pipeline focused on neuropsychiatric disorders. The company's lead product candidate, GlyphAllo TM, is a novel oral prodrug targeting depression and anxiety, with Phase 2b trials underway. The offering includes underwriters such as Goldman Sachs and J.P. Morgan, and the company plans to list on the Nasdaq Global Market under the symbol 'SPTX'.

DRS/A amended

Seaport Therapeutics, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to list on the Nasdaq Global Market under the symbol 'SPTX.' The company, an emerging growth company, focuses on developing novel therapies for neuropsychiatric disorders using its proprietary Glyph platform. The current DRS/A filing includes details about the IPO price range, underwriters, and risk factors, with a focus on its lead candidate, GlyphAllo, a prodrug of allopregnanolone for treating depression and anxiety. The filing also references an asset transfer from PureTech Health LLC and PureTech LYT Inc., which expanded its intellectual property and technology portfolio.

DRS filed

Seaport Therapeutics, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to list on the Nasdaq Global Market under the symbol 'SPTX.' The company is a clinical-stage biotechnology firm focused on developing innovative oral therapies for neuropsychiatric disorders using its proprietary Glyph TM platform, which targets lymphatic delivery to improve drug bioavailability and reduce side effects. Its lead candidate, GlyphAllo TM (SPT-300), is in Phase 1 and 2a trials for major depressive disorder. The filing indicates the company is an 'emerging growth company' and 'smaller reporting company,' qualifying for reduced disclosure requirements. The IPO is contingent on meeting Nasdaq listing standards, and the offering includes underwriters such as Goldman Sachs, J.P. Morgan, and others.